Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

By Smith Ian  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 133-143

Springer Publishing Company

Access to resources Recommend Favorite

Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis

By            

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 720-724

Science Publishers

Access to resources Recommend Favorite

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

By            

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2825-2832

Spandidos Publications

Access to resources Recommend Favorite

Effect of Margin Width on Local Recurrence in Triple-Negative Breast Cancer Patients Treated with Breast-Conserving Therapy

By Pilewskie Melissa   Ho Alice   Orell Emily   Stempel Michelle   Chen Yu   Eaton Anne   Patil Sujata   Morrow Monica  

Annals of Surgical Oncology, Vol. 21, Iss. 4, 2014-04 ,pp. : 1209-1214

Springer Publishing Company

Access to resources Recommend Favorite

Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients

By  

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2549-2559

Spandidos Publications

Access to resources Recommend Favorite